Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01232283 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 413
- Enrollment target
NCT01232283 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 413 participants.
The verdict
NCT01232283, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 413 participants
- Enrollment target
Study Summary
This study will evaluate the effects of an experimental (being tested) study drug called apremilast. Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis. The purpose of this study is to test apremilast and compare its effects to placebo (an inactive substance which contains no medicine but is in the same form as the drug). This study will test efficacy (improvement of signs and symptoms) and safety of apremilast in patients with moderate to severe psoriasis.
Interventions
- DRUG Placebo
- DRUG Apremilast
- OTHER Topical or Phototherapy Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 413 participants |
| Start Date | 2010-11-22 |
| Est. Completion | 2016-11-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01232283
The ClinicalTrials.gov registry entry for NCT01232283 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 413 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01232283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01232283 about?
NCT01232283 is a clinical study titled "Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.". This study will evaluate the effects of an experimental (being tested) study drug called apremilast. Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis. The purpose of this study is to test apremilast and compare its effects to p...
What is the current status of trial NCT01232283?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 413 participants. The study started on 2010-11-22. Estimated completion is 2016-11-30.
What interventions are being tested in trial NCT01232283?
The interventions under investigation include: Placebo (DRUG), Apremilast (DRUG), Topical or Phototherapy Therapy (OTHER).
Who is sponsoring clinical trial NCT01232283?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.